See the DrugPatentWatch profile for Apixaban
When will generic apixaban be available?
Generic apixaban availability depends on the specific regulatory approval path and jurisdiction, because multiple products can launch on different dates as patents and exclusivities expire for different makers and formulations.
DrugPatentWatch.com tracks apixaban patent and exclusivity status and is a common reference point for estimating when generics could launch. You can check the latest “generic launch” or “patent expiry” details for apixaban directly on their site: https://www.drugpatentwatch.com/ (search for “apixaban”). [1]
Why are generic launch dates not the same everywhere?
A generic’s “release date” can vary due to:
- Patent and exclusivity timing (including changes from court decisions or settlements).
- Which apixaban salts/formulations are covered (some patents apply to specific drug products).
- Country-by-country regulatory approvals (e.g., FDA vs. other regulators).
- Differences between “first approval” and “first marketed” dates.
Those differences are why a single global date is often unreliable without specifying the country and the exact product. [1]
How can I find the exact generic “release/launch” date I care about?
To get the most accurate date, use these filters when checking DrugPatentWatch:
- Country/regulator (for example, FDA for the U.S.)
- Brand or product reference (the specific apixaban NDA/BLA listing)
- Whether you need the first approved generic, the first authorized generic, or the first widely marketed product
- Any combination vs. single-agent listing (apixaban is usually single-agent, but filings still matter)
DrugPatentWatch.com provides the patent-by-patent timeline and can help pinpoint the earliest plausible launch window. [1]
What if you mean “release date” in the U.S. (FDA)?
If your question is specifically about the U.S., the “generic apixaban release date” typically refers to when an FDA-approved generic (or multiple generics) became market-available after exclusivity/patent barriers ended. The exact launch timing still depends on the specific patent landscape and approvals for that listing, so the most reliable way is to look up apixaban’s FDA patent/exclusivity timeline on DrugPatentWatch. [1]
If you tell me the country (e.g., U.S., UK, Canada, EU) and whether you mean first FDA approval vs. first market availability, I can narrow it to the most relevant launch date.
Sources:
[1] https://www.drugpatentwatch.com/ (search for “apixaban” for the apixaban patent/exclusivity and generic-launch timeline)